These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 33717135)

  • 1. Changes in the Peripheral Blood Treg Cell Proportion in Hepatocellular Carcinoma Patients After Transarterial Chemoembolization With Microparticles.
    Ren Z; Yue Y; Zhang Y; Dong J; Liu Y; Yang X; Lin X; Zhao X; Wei Z; Zheng Y; Wang T
    Front Immunol; 2021; 12():624789. PubMed ID: 33717135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of transcatheter arterial chemoembolization on cellular immune function and regulatory T cells in patients with hepatocellular carcinoma.
    Liao J; Xiao J; Zhou Y; Liu Z; Wang C
    Mol Med Rep; 2015 Oct; 12(4):6065-71. PubMed ID: 26239573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of transarterial chemoembolization on regulatory T cell and its subpopulations in patients with hepatocellular carcinoma.
    Park H; Jung JH; Jung MK; Shin EC; Ro SW; Park JH; Kim DY; Park JY; Han KH
    Hepatol Int; 2020 Mar; 14(2):249-258. PubMed ID: 32072464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical prognostic value of CD4+CD25+FOXP3+regulatory T cells in peripheral blood of Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma patients.
    Li F; Guo Z; Lizée G; Yu H; Wang H; Si T
    Clin Chem Lab Med; 2014 Sep; 52(9):1357-65. PubMed ID: 24646790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of dosage of anticancer agents during transcatheter arterial chemoembolization on T cell subsets in patients with hepatocellular carcinoma.
    Lu W; Li YH; He XF; Chen Y; Zeng QL; Qiu YR
    Di Yi Jun Yi Da Xue Xue Bao; 2002 Jun; 22(6):524-6. PubMed ID: 12297475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in immunological function after treatment with transarterial chemoembolization plus radiofrequency ablation in hepatocellular carcinoma patients.
    Guan HT; Wang J; Yang M; Song L; Tong XQ; Zou YH
    Chin Med J (Engl); 2013; 126(19):3651-5. PubMed ID: 24112158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transarterial chemoembolization with gelatin sponge microparticles for barcelona clinic liver cancer Stage C and large hepatocellular carcinoma: Initial clinical experience.
    Zhou J; Liu Y; Ren Z; Zhang Y; Zhang M
    J Cancer Res Ther; 2017; 13(5):767-772. PubMed ID: 29237901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory T Cells, IL10 and IL6 in HCV Related Hepatocellular Carcinoma after Transarterial Chemoembolization (TACE).
    Hassan EA; Ahmed EH; Nafee AM; El-Gafary N; Hetta HF; El-Mokhtar MA
    Egypt J Immunol; 2019 Jan; 26(1):69-78. PubMed ID: 31332997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transarterial Chemoembolisation (TACE) with Degradable Starch Microspheres (DSM) and Anthracycline in Patients with Locally Extensive Hepatocellular Carcinoma (HCC): Safety and Efficacy.
    Gross A; Albrecht T
    Cardiovasc Intervent Radiol; 2020 Mar; 43(3):402-410. PubMed ID: 31705244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes of CD4(+) CD25 (+) regulatory T cells in peripheral blood in patients with hepatocellular carcinoma before and after TACE.
    Xiong B; Feng G; Luo S; Liang H; Qiu L; Zheng C; Liu X; Zhou G
    J Huazhong Univ Sci Technolog Med Sci; 2008 Dec; 28(6):645-8. PubMed ID: 19107357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcatheter Arterial Chemoembolization With Gelatin Sponge Microparticles Treated for BCLC Stage B Hepatocellular Carcinoma: A Single Center Retrospective Study.
    Kamran AU; Liu Y; Li FE; Liu S; Wu JL; Zhang YW
    Medicine (Baltimore); 2015 Dec; 94(52):e2154. PubMed ID: 26717358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased circulating Th17 cells after transarterial chemoembolization correlate with improved survival in stage III hepatocellular carcinoma: a prospective study.
    Liao Y; Wang B; Huang ZL; Shi M; Yu XJ; Zheng L; Li S; Li L
    PLoS One; 2013; 8(4):e60444. PubMed ID: 23565248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC): long-term results from a single-center 137-patient cohort prospective study.
    Orlacchio A; Chegai F; Roma S; Merolla S; Bosa A; Francioso S
    Radiol Med; 2020 Jan; 125(1):98-106. PubMed ID: 31583558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma: a rationale for combining selective internal radiation therapy (SIRT) and immunotherapy.
    Craciun L; de Wind R; Demetter P; Lucidi V; Bohlok A; Michiels S; Bouazza F; Vouche M; Tancredi I; Verset G; Garaud S; Naveaux C; Galdon MG; Gallo KW; Hendlisz A; Derijckere ID; Flamen P; Larsimont D; Donckier V
    BMC Cancer; 2020 Feb; 20(1):135. PubMed ID: 32075608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epirubicin is More Effective than Miriplatin in Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma.
    Shirono T; Iwamoto H; Niizeki T; Shimose S; Nakano M; Satani M; Okamura S; Noda Y; Kamachi N; Kuromatsu R; Sakai M; Nomiyama M; Kuwano T; Tanaka M; Koga H; Torimura T
    Oncology; 2019; 96(2):79-86. PubMed ID: 30293080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Transcatheter Arterial Chemoembolization Combined with Argon-Helium Cryosurgery System on the Changes of NK Cells and T Cell Subsets in Peripheral Blood of Hepatocellular Carcinoma Patients.
    Huang M; Wang X; Bin H
    Cell Biochem Biophys; 2015 Dec; 73(3):787-92. PubMed ID: 27259326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Microparticle Transarterial Chemoembolization (mTACE) on myeloid-derived suppressor cell subtypes in hepatocellular carcinoma: Clinical correlations and therapeutic implications.
    Yue Y; Ren Z; Wang Y; Liu Y; Yang X; Wang T; Bai Y; Zhou H; Chen Q; Li S; Zhang Y
    Immun Inflamm Dis; 2024 Sep; 12(9):e70007. PubMed ID: 39222024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Association between Peripheral Th17, Th1, IL-17, and IFN-γ Levels and TACE Response in Patients with Unresectable Hepatocellular Carcinoma with or without Cirrhosis.
    Hasan I; Gani RA; Lesmana LA; Kresno SB; Pandelaki J; Suwarto S
    Acta Med Indones; 2020 Oct; 52(4):326-333. PubMed ID: 33377877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
    Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
    J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of gelatin sponge microparticles in a rabbit VX2 liver tumor model of hepatic arterial chemoembolization.
    Zhang YW; Ao J; Liu Y; Qiao MX; Yang XL; Tang SX; Li C; Xu K
    Tumour Biol; 2014 Nov; 35(11):10905-10. PubMed ID: 25085588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.